Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Mol Biol Rep ; 47(4): 2509-2519, 2020 Apr.
Article in English | MEDLINE | ID: mdl-32088817

ABSTRACT

Early diagnosis and treatment of colorectal cancer (CRC) are important for improving patients' survival. Metadherin is an oncogene that plays a pivotal role in carcinogenesis and can be suggested as a cancer biomarker. This study aimed to elucidate the efficacy of serum Metadherin mRNA expression as a potential non-invasive biomarker for early diagnosis of CRC in relation to other screening markers as carcinoembryonic antigen (CEA), carbohydrate antigen 19.9 (CA19.9) and Fecal occult blood (FOB) and also to assess its relationship with the tumor stage and survival rate. A convenience series of 86 CRC cases (group I) were recruited with 78 subjects as controls (group II). Serum Metadherin mRNA expression level was determined using reverse transcription polymerase chain reaction (RT-PCR). Serum Metadherin mRNA expression level was significantly elevated in CRC cases when compared with controls (P < 0.001). For CRC diagnosis; Receiver operator characteristic (ROC) analyses revealed that the diagnostic accuracy of serum Metadherin mRNA (AUC = 0.976) was significantly higher than other routine CRC screening markers as CEA, CA19.9 and FOB. The combined accuracy of these markers (AUC = 0.741) was increased when used with serum Metadherin mRNA (AUC = 0.820). High serum Metadherin mRNA expression was associated with poorly differentiated histological grade, advanced tumor stage and lower survival rate. AUC of Metadherin was 0.820 for differentiating advanced versus early tumor stages. Serum Metadherin mRNA expression is a useful non-invasive biomarker for CRC. It can be used for screening and early diagnosis of CRC and can increase the efficacy of other routine CRC screening markers when it is estimated in CRC patients with them. It is also associated with advanced tumor stage and a lower survival rate.


Subject(s)
Biomarkers, Tumor/genetics , Colorectal Neoplasms/genetics , Membrane Proteins/genetics , RNA-Binding Proteins/genetics , Adult , Aged , Area Under Curve , Biomarkers, Tumor/blood , CA-19-9 Antigen/analysis , CA-19-9 Antigen/blood , Carcinoembryonic Antigen/analysis , Carcinoembryonic Antigen/blood , Case-Control Studies , Colorectal Neoplasms/diagnosis , Colorectal Neoplasms/metabolism , Early Detection of Cancer/methods , Female , Humans , Male , Membrane Proteins/blood , Membrane Proteins/metabolism , Middle Aged , Occult Blood , Prognosis , RNA, Messenger/analysis , RNA-Binding Proteins/blood , RNA-Binding Proteins/metabolism , ROC Curve
SELECTION OF CITATIONS
SEARCH DETAIL
...